Propranolol treatment for hemangioma of infancy: risks and recommendations.
Reads0
Chats0
TLDR
This work presents two infants treated with propranolol, who suffered complications and proposes a treatment protocol to minimize potential adverse events.Abstract:
Hemangioma of infancy is a condition that may be associated with significant morbidity. While evidence most supports the use of corticosteroids, there is no well-defined or Federal Drug Administration (FDA)-approved systemic therapy for hemangioma of infancy. All currently used treatments have significant risks. Dramatic improvement of complicated hemangioma of infancy to propranolol was recently reported, but details for initiating therapy, monitoring, and potential risks were not included. We present two infants treated with propranolol, who suffered complications and propose a treatment protocol to minimize potential adverse events.read more
Citations
More filters
Journal ArticleDOI
Basic and Clinical Pharmacology
TL;DR: This book succeeds Review of Medical Pharmacology, by Meyers, Jawetz, and Goldfien, and deals with relevant information regarding the clinical use of drugs on the various battlefields.
Journal ArticleDOI
Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action.
C.H. Storch,Peter H. Hoeger +1 more
TL;DR: Oral propranolol is a very recent therapeutic option for complicated IH with impressive efficacy and generally good tolerance, and its mechanisms of action in IH are presented.
Journal ArticleDOI
Initiation and Use of Propranolol for Infantile Hemangioma: Report of a Consensus Conference
Beth A. Drolet,Peter C. Frommelt,Sarah L. Chamlin,Anita N. Haggstrom,Nancy M. Bauman,Yvonne E. Chiu,Robert H. Chun,Maria C. Garzon,Kristen E. Holland,Leonardo Liberman,Susan G. MacLellan-Tobert,Anthony J. Mancini,Denise W. Metry,Katherine B. Puttgen,Marcia Seefeldt,Robert Sidbury,Kendra M. Ward,Francine Blei,Eulalia Baselga,Laura D. Cassidy,David H. Darrow,Shawna Joachim,Eun Kyung M. Kwon,Kari Martin,Jonathan A. Perkins,Dawn H. Siegel,Robert J. Boucek,Ilona J. Frieden +27 more
TL;DR: The multidisciplinary team agreed on a number of recommendations that arose from a review of existing evidence, including when to treat complicated IH; contraindications and pretreatment evaluation protocols; propranolol use in PHACE syndrome; formulation, target dose, and frequency of proPRanolol; initiation of propr ethanol in infants; cardiovascular monitoring; ongoing monitoring; and prevention of hypoglycemia.
Journal ArticleDOI
A Randomized Controlled Trial of Propranolol for Infantile Hemangiomas
TL;DR: Propranolol hydrochloride administered orally at 2 mg/kg per day reduced the volume, color, and elevation of focal and segmental IH in infants younger than 6 months and children up to 5 years of age.
Journal ArticleDOI
Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants.
Marlies de Graaf,Johannes M.P.J. Breur,Martine Raphael,Marike Vos,Corstiaan C. Breugem,Suzanne G.M.A. Pasmans +5 more
TL;DR: Propranolol appears to be an effective treatment option for IH even in the nonproliferative phase and after the first year of life and potentially harmful adverse effects include hypoglycemia, bronchospasm, and hypotension.
References
More filters
Journal ArticleDOI
Propranolol for Severe Hemangiomas of Infancy
Christine Léauté-Labrèze,Dumas de la Roque E,Thomas Hubiche,Franck Boralevi,Thambo Jb,Alain Taieb +5 more
TL;DR: It is observed in 11 children that propranolol can inhibit the growth of infantile capillary hemangiomas and this work is hopeful that this discovery will help improve the prognosis of these patients.
Journal ArticleDOI
Basic and Clinical Pharmacology
TL;DR: This book succeeds Review of Medical Pharmacology, by Meyers, Jawetz, and Goldfien, and deals with relevant information regarding the clinical use of drugs on the various battlefields.
Journal ArticleDOI
Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment.
Anita N. Haggstrom,Beth A. Drolet,Eulalia Baselga,Sarah L. Chamlin,Maria C. Garzon,Kimberly A. Horii,Anne W. Lucky,Anthony J. Mancini,Denise W. Metry,Brandon D. Newell,Amy J. Nopper,Ilona J. Frieden +11 more
TL;DR: Large size, facial location, and/or segmental morphology are the most important predictors of poor short-term outcomes as measured by complication and treatment rates in infantile hemangiomas.
Journal ArticleDOI
Infantile hemangiomas: how common are they? A systematic review of the medical literature.
TL;DR: The objective of this study is to critically re‐examine the literature reporting the incidence of infantile hemangiomas to determine if the true incidence is actually known and to more accurately define the incidence and potential impact of this common vascular tumor of infancy.
Journal ArticleDOI
Patterns of cerebral injury and neurodevelopmental outcomes after symptomatic neonatal hypoglycemia.
TL;DR: Pregnancy-induced hypertension, a family history of seizures, emergency cesarean section, and the need for resuscitation were more common among case subjects than control subjects and patterns of injury associated with symptomatic neonatal hypoglycemia were more varied than described previously.
Related Papers (5)
Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action.
C.H. Storch,Peter H. Hoeger +1 more